HCV hotline facilitates Hepatitis C elimination during the COVID‐19 pandemic

The COVID‐19 pandemic necessitates healthcare restrictions that also affected ongoing hepatitis C virus (HCV) elimination efforts. We assessed the value of a physician‐operated HCV hotline on treatment and cure rates throughout the pandemic. All HCV patients undergoing HCV therapy at the Vienna General Hospital from 2019 to 2021 were included. An HCV hotline was established in 2019 and provided services including phone calls, text messages and voicemails. Patients were stratified by date of HCV therapy: 2019 (pre‐COVID) vs. 2020/2021 (during‐COVID) and use of the HCV hotline: users vs. non‐users. Overall, 220 patients were included (pre‐COVID: n = 91 vs. during‐COVID: n = 129). The prevalence of intravenous drug use (60.5%) and alcohol abuse (24.8%) was high during COVID. During COVID, the number of DAA treatment starts declined by 24.2% (n = 69) in 2020 and by 34.1% (n = 60) in 2021 vs. pre‐COVID (n = 91, 100%). Significantly more patients used the HCV hotline during‐COVID (95.3%) vs. pre‐COVID (65.9%; p < .001). Sustained virologic response (SVR) was 84.6% pre‐COVID and 86.0% during‐COVID. HCV hotline users achieved higher SVR rates during‐COVID (88.2% vs. 33.3%, p = .004), but also pre‐COVID (96.7% vs. 61.3%, p < .001) compared with non‐users. Considering only patients with completed DAA treatments, SVR rates remained similarly high during‐COVID (96.9%) versus pre‐COVID (98.1%). HCV treatment initiations decreased during‐COVID but importantly, nearly all DAA‐treated HCV patients used the HCV hotline during the COVID pandemic. Overall, the SVR rate remained at 88.2% during COVID and was particularly high in HCV phone users—most likely due to facilitation of adherence.

[1]  C. D. F. de Souza,et al.  Impact of the COVID-19 pandemic on hepatitis C diagnosis in Brazil: Is the global hepatitis C elimination strategy at risk? , 2021, Journal of Hepatology.

[2]  M. Mandorfer,et al.  Outcomes of an HCV elimination program targeting the Viennese MSM population , 2021, Wiener klinische Wochenschrift.

[3]  M. Trauner,et al.  COVID‐19‐Related Downscaling of In‐Hospital Liver Care Decreased Patient Satisfaction and Increased Liver‐Related Mortality , 2021, Hepatology communications.

[4]  M. Heo,et al.  High HCV cure rates among people who inject drugs and have suboptimal adherence: A patient-centered approach to HCV models of care. , 2021, The International journal on drug policy.

[5]  M. Trauner,et al.  Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence , 2020, Wiener klinische Wochenschrift.

[6]  M. Buti,et al.  Impact of the COVID-19 pandemic on HCV elimination in Spain , 2020, Journal of Hepatology.

[7]  S. Llerena,et al.  Telemedicine efficiently improves access to hepatitis C management to achieve HCV elimination in the penitentiary setting. , 2020, The International journal on drug policy.

[8]  J. A. Cook,et al.  Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study , 2020, Journal of Hepatology.

[9]  R. Sterling,et al.  Telemedicine HCV treatment in department of corrections results in high SVR in era of direct‐acting antivirals , 2020, Journal of viral hepatitis.

[10]  P. Reese,et al.  In‐Person Outreach and Telemedicine in Liver and Intestinal Transplant: A Survey of National Practices, Impact of Coronavirus Disease 2019, and Areas of Opportunity , 2020, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[11]  J. Pawlotsky,et al.  Impact of COVID-19 on global HCV elimination efforts , 2020, Journal of Hepatology.

[12]  T. Berg,et al.  Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic , 2020, JHEP Reports.

[13]  J. Pawlotsky.  COVID-19 and the liver-related deaths to come , 2020, Nature Reviews Gastroenterology & Hepatology.

[14]  E. Buscarini,et al.  High rates of 30-day mortality in patients with cirrhosis and COVID-19 , 2020, Journal of Hepatology.

[15]  Yuan Zhang,et al.  Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis , 2020, The Lancet.

[16]  X. Qi,et al.  High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry , 2020, Journal of Hepatology.

[17]  Ahmad Khan,et al.  Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study , 2020, Gastroenterology.

[18]  Devin M Mann,et al.  COVID-19 transforms health care through telemedicine: Evidence from the field , 2020, J. Am. Medical Informatics Assoc..

[19]  R. Fontana,et al.  Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement , 2020, Hepatology.

[20]  E. Tapper,et al.  The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care , 2020, Journal of Hepatology.

[21]  M. Serper,et al.  Telemedicine in Liver Disease and Beyond: Can the COVID‐19 Crisis Lead to Action? , 2020, Hepatology.

[22]  T. Berg,et al.  Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper , 2020, JHEP Reports.

[23]  W. Ko,et al.  Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status , 2020, International Journal of Antimicrobial Agents.

[24]  T. Reiberger,et al.  Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs—First real world data from Austria , 2020, PloS one.

[25]  Yunpeng Ji,et al.  Potential association between COVID-19 mortality and health-care resource availability , 2020, The Lancet Global Health.

[26]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[27]  Caitlin E. Coombes,et al.  The Current and Future Use of Telemedicine in Infectious Diseases Practice , 2019, Current Infectious Disease Reports.

[28]  T. Asselah,et al.  Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[29]  B. Tofighi,et al.  Technology Use Patterns Among Patients Enrolled in Inpatient Detoxification Treatment. , 2019, Journal of addiction medicine.

[30]  Rafael Stern,et al.  Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. , 2016, Journal of hepatology.

[31]  M. Trauner,et al.  Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease , 2016, AIDS.

[32]  Steffanie A Strathdee,et al.  Factors associated with patterns of mobile technology use among persons who inject drugs , 2016, Substance abuse.

[33]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[34]  O. Aasland,et al.  Alcohol consumption and related problems among primary health care patients: WHO collaborative project on early detection of persons with harmful alcohol consumption--I. , 1993, Addiction.

[35]  H Stibler,et al.  Carbohydrate-deficient transferrin in serum: a new marker of potentially harmful alcohol consumption reviewed. , 1991, Clinical chemistry.

[36]  X. Forns,et al.  Recommendations on Treatment of Hepatitis C 2015 , 2015 .